Yes, Ozempic is a GLP-1 drug. Specifically, it belongs to a class of medications called GLP-1 receptor agonists. Its active ingredient is semaglutide, and it works by mimicking a natural hormone your body already produces to regulate blood sugar and appetite. The FDA classifies it as “a glucagon-like peptide 1 (GLP-1) receptor agonist,” which is the formal name for this drug class.
What GLP-1 Drugs Actually Do
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It signals your pancreas to produce insulin, which lowers blood sugar. It also suppresses glucagon, a hormone that raises blood sugar, creating a two-pronged effect on glucose control. On top of that, GLP-1 slows down how quickly food leaves your stomach, which helps you feel full longer and prevents blood sugar spikes after meals.
GLP-1 receptor agonist drugs like Ozempic are synthetic versions of this hormone, engineered to last much longer in the body than the natural version. Your body’s own GLP-1 breaks down within minutes. Semaglutide, by contrast, stays active long enough to be injected just once a week.
What Ozempic Is Approved For
Ozempic currently has three FDA-approved uses, all tied to type 2 diabetes:
- Blood sugar control in adults with type 2 diabetes, alongside diet and exercise
- Cardiovascular risk reduction in adults with type 2 diabetes and established heart disease, lowering the risk of heart attack, stroke, and cardiovascular death
- Kidney protection in adults with type 2 diabetes and chronic kidney disease, reducing the risk of kidney function decline
Ozempic is not FDA-approved for weight loss, even though it’s widely prescribed off-label for that purpose. Wegovy, which contains the same active ingredient (semaglutide) at a higher maximum dose of 2.4 mg versus Ozempic’s 2 mg, is the version specifically approved for weight management.
How Ozempic Compares to Other GLP-1 Drugs
Ozempic is one of several GLP-1 receptor agonists on the U.S. market. Others include dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta and Bydureon), and lixisenatide (Adlyxin). Semaglutide also comes in a pill form called Rybelsus for people who prefer not to inject.
There’s also a newer related class called dual GLP-1/GIP receptor agonists, which activate two gut hormone receptors instead of one. Tirzepatide (Mounjaro) is the main drug in this category. These are sometimes grouped with GLP-1 drugs in casual conversation, but they work through a slightly different mechanism.
How You Take It
Ozempic is a once-weekly injection given under the skin of the abdomen, thigh, or upper arm. The dose starts low and increases gradually to reduce side effects. You begin at 0.25 mg weekly for the first four weeks, then move up to 0.5 mg. From there, your dose can be increased further based on your response and your doctor’s recommendations. The maximum dose is 2 mg once a week.
This slow ramp-up matters because many of the drug’s side effects are dose-dependent and hit hardest when you first start or increase the dose.
How Well It Works
In clinical trials, patients taking semaglutide saw their A1C (a measure of average blood sugar over roughly three months) drop by about 1.42 percentage points more than those on placebo. For context, an A1C reduction of 1% or more is considered clinically meaningful and is associated with significantly lower risk of diabetes complications.
Common Side Effects
Digestive issues are the most frequent side effects by a wide margin. In a two-year study of semaglutide in people with overweight or obesity, 82.2% of patients on the drug experienced mild to moderate gastrointestinal side effects, compared with 53.9% on placebo. The most common complaints are nausea, vomiting, diarrhea, constipation, stomach pain, and bloating.
The good news is that these effects tend to ease up. Most patients find their gastrointestinal symptoms improve after about 20 weeks of use as the body adjusts to the medication. The gradual dose increases are specifically designed to make this adjustment period more tolerable.
Safety Warnings to Know About
Ozempic carries a boxed warning (the FDA’s most serious type) about thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors in rodents at doses similar to what humans take. Whether this risk applies to people remains unknown, but as a precaution, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
If you’re taking Ozempic, symptoms worth watching for include a lump or mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. These could indicate thyroid changes that need evaluation.